Products
Latest News
FAQ
Log in
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Newest First
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
Phase 2
Not yet recruiting
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Fruquintinib
Subscribe
First Posted Date
2022-07-07
Last Posted Date
2022-07-07
Lead Sponsor
Weijian Guo
Target Recruit Count
134
Registration Number
NCT05447715
Locations
🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy